Olive vs. Fish Oil IV Nutrition: Systematic Review Finds No Clear Winner

For patients lying in hospital beds unable to eat, intravenous nutrition is not a luxury—it is survival. The question of which formula to drip into their veins, however, remains surprisingly unsettled. A systematic review published in the Journal of Human Nutrition and Dietetics examined six randomized trials comparing olive-oil-based and fish-oil-containing intravenous nutrition formulations in hospitalized adults, searching for evidence that one approach clearly outperforms the other. What the researchers found was inconclusive: no decisive winner, no clear path forward.

Hospitals have long moved away from soybean-oil-based intravenous nutrition, prompted by emerging evidence that alternative lipid sources might confer clinical advantages. Olive oil and fish oil have both been proposed as candidates—olive oil for its antioxidant and anti-inflammatory compounds, fish oil for its omega-3 fatty acids, which serve as building blocks for the body's own anti-inflammatory machinery. The theoretical case for both seemed sound. But theory and practice diverged when researchers actually tested them.

The review team searched four major medical databases and screened more than 3,400 papers. After removing duplicates, excluding studies that did not meet criteria, and filtering out animal research and pediatric trials, they were left with six randomized controlled trials conducted in Spain, Mexico, and Turkey. The participants ranged in age from their mid-40s to early 70s and included postoperative patients, people with type 2 diabetes, those in septic shock, and patients with intestinal failure—the kinds of critically ill individuals for whom intravenous feeding becomes a lifeline. All received nutrition support for at least four days.

When the researchers examined the results, they encountered a landscape of conflicting signals. One low-risk trial found that patients receiving fish oil experienced significantly more infections during the first week of feeding, though overall infection rates between the two groups were not dramatically different—54 percent in the olive oil group versus 47 percent in the fish oil group. A different trial reported the opposite pattern: non-septic infections occurred far more frequently in olive oil recipients than in those given fish oil for five or more days, roughly 79 percent compared to 23 percent. Individual studies reported lower glucose levels, reduced bilirubin, and improved inflammatory markers with fish oil in some cases, while other trials showed oxidative stress markers improving with olive oil. None of these findings held consistently across the evidence base.

The fundamental problem was heterogeneity. The six trials did not use uniform formulations. Fish oil appeared in every study, but never alone—it was mixed with other lipid emulsions or added to olive-oil-based solutions in varying concentrations. This variation meant researchers could not establish precise dosing or directly compare equivalent amounts across studies. The small number of trials and the wide scatter of outcomes made a meta-analysis impossible, the statistical tool that might have revealed a larger pattern beneath the noise.

Three of the six trials carried low risk of bias, two were judged to have high risk, and one raised concerns. The inconsistency extended to every outcome examined: infection rates, inflammatory markers like interleukin-8 and C-reactive protein, liver function, glucose control, and oxidative stress. Hospital length of stay, perhaps the most clinically meaningful measure, showed no significant difference between the two approaches.

What emerged from this review was not a recommendation but a call for better research. The evidence suggests that moving beyond soybean oil offers potential benefits, but whether olive or fish oil formulations deliver those benefits more reliably remains unknown. Hospitalized patients who cannot eat by mouth depend on these formulations to survive their illness and recover. They deserve evidence that is clear, consistent, and actionable. For now, clinicians must make choices in the absence of definitive guidance, and researchers must design more rigorous trials with standardized formulations and dosing protocols to finally answer the question: which lipid emulsion truly serves these vulnerable patients best?